sparsentan
25-683
Phase 1 small_molecule active
Quick answer
sparsentan for Proteinuric Renal Disease is a Phase 1 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Proteinuric Renal Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active